Who owns KARYOPHARM THERAPEUTICS INC COM NEW?
- Ticker: KPTI
- CUSIP Number: 48576u205
Tip: Access positions for across all investors
Analyze quarterly positions in Karyopharm Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Karyopharm Therapeutics stock
Who bought or sold KARYOPHARM THERAPEUTICS INC COM NEW this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Ikarian Capital | 2.6M | $14M | 373% | Mar 2026 |
|
| Commodore Capital | 2.0M | $11M | 100% | Mar 2026 |
|
| RA Capital Management | 1.9M | $11M | 100% | Mar 2026 |
|
| Adage Capital Partners GP | 1.8M | $10M | 329% | Mar 2026 |
|
| Susquehanna International | 1.3M | $7.3M | 58% | Mar 2026 |
|
| Caption Management | 1.2M | $6.6M | 100% | Mar 2026 |
|
| Goldman Sachs Group | 948k | $5.3M | 100% | Mar 2026 |
|
| Catalio Capital Management | 898k | $5.0M | 528% | Mar 2026 |
|
| Boothbay Fund Management | 750k | $4.2M | 419% | Mar 2026 |
|
| Squadron Capital Management | 750k | $4.2M | 100% | Mar 2026 |
|
| Vanguard Capital Management | 740k | $4.1M | 100% | Mar 2026 |
|
| Jane Street | 594k | $3.3M | 550% | Mar 2026 |
|
| Millennium Management | 512k | $2.8M | 100% | Mar 2026 |
|
| Citadel Advisors | 508k | $2.8M | 275% | Mar 2026 |
|
| Affinity Asset Advisors | 500k | $2.8M | -44% | Mar 2026 |
|
| Avidity Partners Management | 464k | $2.6M | 245% | Mar 2026 |
|
| Soleus Capital Management | 440k | $2.5M | 0% | Mar 2026 |
|
| ADAR1 Capital Management | 342k | $1.9M | 584% | Mar 2026 |
|
| Boxer Capital Management | 303k | $1.7M | 20% | Mar 2026 |
|
| Davidson Kempner Capital Management | 300k | $1.7M | -3% | Mar 2026 |
|
| Eversept Partners | 300k | $1.7M | 100% | Mar 2026 |
|
| Acorn Capital Advisors | 288k | $1.6M | 100% | Mar 2026 |
|
| Jump Financial | 262k | $1.5M | 387% | Mar 2026 |
|
| Trexquant Investment | 258k | $1.4M | 518% | Mar 2026 |
|
| Ally Bridge Group | 250k | $1.4M | 100% | Mar 2026 |
|
| Acadian Asset Management | 249k | $1.4M | 6582% | Mar 2026 |
|
| BlackRock | 245k | $1.4M | -1% | Mar 2026 |
|
| Diadema Partners | 241k | $1.3M | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 212k | $1.2M | 100% | Mar 2026 |
|
| Geode Capital Management | 206k | $1.1M | 10% | Mar 2026 |
|
| UBS Group | 194k | $1.1M | 119% | Mar 2026 |
|
| Group One Trading | 192k | $1.1M | 87% | Mar 2026 |
|
| Balyasny Asset Management | 171k | $951k | 100% | Mar 2026 |
|
| Silverback Asset Management | 165k | $919k | 312% | Mar 2026 |
|
| XTX Topco | 164k | $916k | 1281% | Mar 2026 |
|
| Two Sigma Investments | 151k | $842k | 2% | Mar 2026 |
|
| Marshall Wace | 129k | $716k | 0% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 115k | $640k | 100% | Mar 2026 |
|
| Engineers Gate Manager | 112k | $626k | 100% | Mar 2026 |
|
| Renaissance Technologies | 105k | $587k | 76% | Mar 2026 |
|
| Polygon Management | 103k | $574k | 100% | Mar 2026 |
|
| CAM Group Holding A/S | 100k | $557k | 0% | Mar 2026 |
|
| State Street Corporation | 81k | $450k | 37% | Mar 2026 |
|
| Connor, Clark & Lunn Investment Management | 79k | $441k | 38% | Mar 2026 |
|
| Bridgeway Capital Management | 72k | $400k | 9% | Mar 2026 |
|
| Royal Bank of Canada | 60k | $334k | 100% | Mar 2026 |
|
| DAFNA Capital Management | 46k | $255k | -10% | Mar 2026 |
|
| Northern Trust | 39k | $215k | 33% | Mar 2026 |
|
| Zimmer Partners | 38k | $209k | 100% | Mar 2026 |
|
| Centiva Capital | 34k | $188k | 100% | Mar 2026 |
|
| China Universal Asset Management | 30k | $167k | 100% | Mar 2026 |
|
| Point72 Asset Management | 30k | $167k | 100% | Mar 2026 |
|
| Baird Financial | 30k | $166k | 6% | Mar 2026 |
|
| Susquehanna Portfolio Strategies | 25k | $139k | 100% | Mar 2026 |
|
| Bank of America Corporation | 20k | $109k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 19k | $108k | 100% | Mar 2026 |
|
| Morgan Stanley | 19k | $104k | 110% | Mar 2026 |
|
| Invesco | 17k | $93k | 100% | Mar 2026 |
|
| Velan Capital Investment Management | 15k | $84k | 100% | Mar 2026 |
|
| Charles Schwab Investment Management | 13k | $75k | 100% | Mar 2026 |
|
| Hsbc Holdings | 12k | $66k | 100% | Mar 2026 |
|
| Bank of New York Mellon | 11k | $64k | 3% | Mar 2026 |
|
| Vanguard Global Advisers | 8.2k | $46k | 100% | Mar 2026 |
|
| Barclays | 7.4k | $41k | 81% | Mar 2026 |
|
| Citigroup | 4.9k | $28k | 100% | Mar 2026 |
|
| TD Waterhouse Canada | 3.2k | $19k | 0% | Mar 2026 |
|
| Rockefeller Capital Management | 733.00 | $4.1k | 0% | Mar 2026 |
|
| FMR | 665.00 | $3.7k | -2% | Mar 2026 |
|
| Persistent Asset Partners | 610.00 | $226.615000 | -97% | Mar 2026 |
|
| Advisor Group Holdings | 402.00 | $2.2k | 43% | Mar 2026 |
|
| Harbour Investments | 285.00 | $1.6k | 235% | Mar 2026 |
|
| Quent Capital | 235.00 | $1.3k | 0% | Mar 2026 |
|
| Mb, Levis & Associates | 100.00 | $557.000000 | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 84.00 | $467.997600 | 2% | Mar 2026 |
|
| SBI Securities | 67.00 | $373.002400 | -9% | Mar 2026 |
|
| Activest Wealth Management | 66.00 | $644.998200 | 0% | Jun 2026 |
|
| Hanson McClain Advisors | 26.00 | $144.999400 | 0% | Mar 2026 |
|
| Advisory Services Network | 12.00 | $66.999600 | 100% | Mar 2026 |
|
| West Branch Capital | 3.00 | $30.000000 | 0% | Jun 2026 |
|
Who sold out of Karyopharm Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Opaleye Management | Dec 2025 | 930k | $6.8M |
| Braidwell | Dec 2025 | 303k | $2.2M |
| Exome Asset Management | Dec 2025 | 296k | $2.2M |
| Ameriprise Financial | Dec 2025 | 277k | $2.0M |
| Walleye Trading Advisors | Dec 2025 | 96k | $704k |
| Two Sigma Advisers | Dec 2025 | 90k | $660k |
| Context Capital Management | Dec 2025 | 63k | $464k |
| Quadrature Capital | Dec 2025 | 60k | $440k |
| Simplex Trading | Dec 2025 | 33k | $242k |
| Springbok Capital Management | Dec 2025 | 29k | $211k |
| Tudor Investment Corporation | Dec 2025 | 13k | $95k |
| Belvedere Trading | Dec 2025 | 12k | $91k |
| CI Private Wealth | Dec 2025 | 10k | $10k |